ASCO Publishes Opinion Piece on the use of PSA in Screening for Prostate Cancer
Despite the fact that prostate cancer is the second leading cause of cancer deaths among men in the United States and that screening potentially reduces the risk of death from prostate cancer through early detection, the USPTF recommended against PSA-based screening for prostate cancer but not against the use of the PSA test for surveillance after diagnosis or treatment of prostate cancer.
In the current opinion piece, ASCO provides evidence from several clinical trials on the benefits of using PSA to screen for prostate cancer. The following results were reported in this PCO. “In one randomized trial, PSA testing in men who would not otherwise have been screened resulted in reduced death rates from prostate cancer, but it is uncertain whether the size of the effect was worth the harms associated with screening and subsequent unnecessary treatment,” the authors wrote. “Although there are limitations to the existing data, there is evidence to suggest that men with longer life expectancy may benefit from PSA testing.”
Please feel free to elaborate on your response to the poll in the comment box below.